

<b>Policy Name</b>	Clinical Policy – Retinal Angiography
<b>Policy Number</b>	1313.00
<b>Department</b>	Clinical Strategy
<b>Subcategory</b>	Medical Management
<b>Original Approval Date</b>	02/06/2018
<b>Current MPC/CCO Approval Date</b>	01/07/2026
<b>Current Effective Date</b>	04/01/2026

**Company Entities Supported (Select All that Apply)**

Superior Vision Benefit Management  
 Superior Vision Services  
 Superior Vision of New Jersey, Inc.  
 Block Vision of Texas, Inc. d/b/a Superior Vision of Texas  
 Davis Vision  
 (Collectively referred to as 'Versant Health' or 'the Company')

**ACRONYMS**

CNV	Choroidal Neovascularization
FA	Fluorescein Angiography
ICG	Indocyanine – Green Angiography

**PURPOSE**

To provide the medical necessity criteria to support the indication(s) for retinal angiography and to render medical necessity determinations. Applicable procedure codes are also defined.

**POLICY**
**A. BACKGROUND**

Retinal angiography includes both fluorescein angiography (FA) and indocyanine-green (ICG) angiography imaging. These images include the retina, choroid, optic disc, fovea, and the macula. Retinal angiographs are not medically necessary either for screening, to simply document the existence of a condition, or as a duplicative or redundant test that does not provide added information.

## **B. Medically Necessary**

Medical necessity for any diagnostic testing, including FA and ICG, begins with pertinent signs, symptoms, or medical history of a condition for which the examining physician needs further information. FA and/or ICG is ordered and performed when the information garnered from the eye exam is insufficient to assess the patient's disease and is medically necessary as an adjunct to evaluation and management of a known disease.

### 1. Fluorescein Angiography (FA)

FA is considered medically necessary as an adjunct to evaluation and management of chorioretinal vascular abnormalities, including the following:

- a. Choroidal neovascularization (CNV),
- b. Noninfective vasculitis,
- c. Age related macular degeneration,
- d. Macular edema,
- e. Intraocular tumors,
- f. Visual loss in systemic disease or acute exudative inflammations, such as toxoplasmosis, optic disc edema, or central serous chorioretinopathy,
- g. Genetic ocular conditions requiring FA to confirm diagnoses, i.e.
  - i. FEVR (familial exudative vitreoretinopathy);<sup>1</sup>
  - ii. Coats disease (often coded as "exudative retinopathy", same as FEVR);<sup>2</sup>
  - iii. Norrie disease;<sup>3</sup>
  - iv. Incontinentia Pigmenti;<sup>4</sup>
  - v. Dyskeratosis Congenita;<sup>5</sup>
  - vi. Sickle Cell Retinopathy;<sup>6</sup>

2. Repeating the FA test may be medically necessary when there is a change in the clinical picture.
3. A repeat FA may also be medically necessary following treatment to detect occult lesions, with or without a clinical change. This will occur most often in CNV and very rarely in other diseases. Otherwise, repeated angiography of the same, unchanged condition is unwarranted.
4. Indocyanine Green (ICG) may be valuable as an adjunct to FA in:
  - a. Retinal neovascularization
  - b. Choroidal neovascularization
  - c. Serous detachment of retinal pigment epithelium
  - d. Hemorrhagic detachment of retinal pigment epithelium
  - e. Retinal hemorrhage

---

<sup>1</sup> Sizmaz, 2015.

<sup>2</sup> Sigler, 2014

<sup>3</sup> Scruggs, 1999.

<sup>4</sup> Tzu, 2013.

<sup>5</sup> AiSabbagh, 2020.

<sup>6</sup> Pahl, 2017.

**C. Not Medically Necessary**

1. Retinal angiography, FA or ICG, is not medically necessary in the following situations:
  - a. When used in an eye without signs, symptoms, serious ophthalmic disease, ocular abnormalities, or contributory medical history,
  - b. When used to confirm a diagnosis that has already been determined,
  - c. Without a documented medical rationale in the medical record.
2. When the angiographic images are taken as baseline documentation of a healthy eye or as screening for potential disease.

**D. Documentation**

Medical necessity must be supported by adequate and complete documentation in the patient's medical record that describes the procedure and the medical rationale for it as in the requirements above. All medical record items must be available upon request to initiate or sustain previous payments. For any retrospective review, a full operative report is needed.

Every page of the record must be legible and include appropriate patient identification information (e.g., complete name, date(s) of service). Services provided/ordered must be authenticated by the physician, in a handwritten or electronic signature. Stamped signatures are not acceptable.

1. Fluorescein angiography (FA) and Indocyanine-green angiography (ICG), separately or together, require a physician's order, and the interpretation and report for the date performed.
2. Only reliable tests are relevant for medical necessity. Reliability is measured with interpretation and report of the following:
  - a. Patient cooperation
  - b. Test findings with interpretation and report. Do not submit normal test results.
  - c. Comparison, when applicable, to any previously completed FA and/or ICG test results.
  - d. Assessment, diagnosis
  - e. Decision impact on treatment, prognosis
  - f. The medical record must contain copies of photographs or digital images and be available upon request.

**E. Procedural Detail**

<b>CPT CODES</b>	
92235	Fluorescein angiography (includes multiframe imaging) with interpretation and report, unilateral or bilateral
92240	Indocyanine-green angiography (includes multiframe imaging) with interpretation and report, unilateral or bilateral

92242	Fluorescein angiography and indocyanine-green angiography (includes multiframe imaging) performed at the same patient encounter with interpretation and report, unilateral or bilateral
<b>Invalid Modifiers</b>	RT, LT, 50

#### **DISCLAIMER and COPYRIGHTS**

This policy is provided for information purposes only and does not constitute medical advice. Versant Health, Inc., and its affiliates (the "Company") do not provide health care services and cannot guarantee any results or outcomes. Treating doctors are solely responsible for determining what services or treatments are provided to their patients. Patients (members) should always consult their doctor before making any decisions about medical care.

Subject to applicable law, compliance with this clinical policy is not a guarantee of coverage or payment. Coverage is based on the terms of an individual's particular benefit plan document, which may not cover the service(s) or procedure(s) addressed in this clinical policy. The terms of the individual's specific benefit plan are always determinative.

Every effort has been made to ensure that the information in this clinical policy is accurate and complete, however the Company does not guarantee that there are no errors in this policy or that the display of this file on a website is without error. The company and its employees are not liable for any errors, omissions, or other inaccuracies in the information, product, or processes disclosed herein. Neither the company nor the employees represent that the use of this information, products, or processes infringes on privately owned rights. In no event shall the Company be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information, product, or process.

**COMPANY'S COPYRIGHT STATEMENT** Except for any copyrights described below, this clinical policy is confidential and proprietary, and no part of this clinical policy may be copied, distributed or used without Versant Health, or its applicable affiliates' express prior written approval.

**AMA COPYRIGHT STATEMENT** CPT®™ is the copyright and registered trademark of the American Medical Association with all rights reserved. Applicable FARS/DFARS apply for government use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, and are not part of CPT. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

#### **RELATED POLICIES AND PROCEDURES**

n/a	
-----	--

**DOCUMENT HISTORY**

<b>Approval Date</b>	<b>Revision</b>	<b>Effective Date</b>
02/06/2018	Initial version	02/06/2018
03/13/2019	Annual review with code additions	03/13/2019
02/19/2020	Annual review; no criteria changes.	04/01/2020
01/06/2021	Annual review; remove statement requiring direct office supervision.	04/01/2021
01/05/2022	Annual review; no criteria changes.	04/01/2022
01/04/2023	Annual review; no criteria changes	04/01/2023
09/20/2023	Administrative review for CMS 2024 final rule Medicare Part C equity: no changes.	n/a
01/03/2024	Annual review. Add indications of macular edema, need to identify ischemia, neo-vascularization, need to locate microaneurysms, and central serous chorioretinopathy.	04/01/2024
01/08/2025	Annual review. Add genetic conditions requiring FA to confirm diagnosis.	05/01/2025
01/07/2026	Annual review; no criteria change.	04/01/2026

**REFERENCES AND SOURCES**

1. AlSabbagh MM. Dyskeratosis congenita: a literature review. *J Dtsch Dermatol Ges.* 2020;18(9):943-967. doi:10.1111/ddg.14268.
2. Berger L, Bühler V, Yzer S. Central Serous Chorioretinopathy - an Overview. *Klin Monbl Augenheilkd.* 2021 Sep;238(9):971-979. English, German. doi: 10.1055/a-1531-5605. Epub 2021 Aug 20. PMID: 34416788.
3. Karasu B, Özkan D, Erdoğan G, et.al. The fluorescein angiographic photo diagnosis of idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome: Outcome of combined therapy. *Photodiagnosis Photodyn Ther.* 2019 Sep; 27:336-339. doi: 10.1016/j.pdpdt.2019.06.013. Epub 2019 Jun 28. PMID: 31260747.
4. Pahl DA, Green NS, Bhatia M, et al. Optical Coherence Tomography Angiography and Ultra-widefield Fluorescein Angiography for Early Detection of Adolescent Sickle Retinopathy. *Am J Ophthalmol.* 2017;183:91-98. doi:10.1016/j.ajo.2017.08.010.
5. Scruggs BA, Reding MQ, Schimmenti LA. NDP-Related Retinopathies. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. *GeneReviews®.* Seattle (WA): University of Washington, Seattle; July 30, 1999.
6. Sigler EJ, Randolph JC, Calzada JI, Wilson MW, Haik BG. Current management of Coats disease. *Surv Ophthalmol.* 2014;59(1):30-46. doi: 10.1016/j.survophthal.2013.03.007.
7. Sizmaz S, Yonekawa Y, T Trese M. Familial Exudative Vitreoretinopathy. *Turk J Ophthalmol.* 2015;45(4):164-168. doi:10.4274/tjo.67699.
8. Tzu JH, Murdock J, Parke DW 3rd, Warman R, Hess DJ, Berrocal AM. Use of fluorescein angiography in incontinentia pigmenti: a case report. *Ophthalmic Surg Lasers Imaging Retina.* 2013;44(1):91-93. doi:10.3928/23258160-20121221-20
9. Zhang P, Wang C, Liang Y, et.al. Retinal and choroidal microvascular features during pregnancy: a systematic review and meta-analysis. *BMJ Open.* 2024 Aug 17;14(8): e087319.

doi: 10.1136/bmjopen-2024-087319. PMID: 39153771; PMCID: PMC11331858.

## SOURCES

1. American Academy of Ophthalmology®. [Age-Related Macular Degeneration Preferred Practice Patterns](#). 2024.. Accessed 10/2025.
2. American Academy of Ophthalmology®, [Retina Summary Benchmarks](#) Preferred Practice Patterns, 2024. Accessed 10/2025.
3. Bennett, T. [The Fundamentals of Fluorescein Angiography](#). The Ophthalmic Photographers' Society, Inc. 2016. Accessed 10/2025.
4. EyeWiki, American Academy of Ophthalmology®. [Fluorescein Angiography](#). 2025. Accessed 10/2025.NIH National Library of Medicine; [Indocyanine-green Angiography](#) 2023. Accessed 10/2025.